Skip to main content
SpringerLink
Log in

Immunotherapy in Waldenstrom’s Macroglobulinemia

  • Chapter
  • First Online:
Waldenström’s Macroglobulinemia

  • 601 Accesses

Abstract

The use of anti-CD20 monoclonal antibody is a standard of care in Waldenström’s macroglobulinemia (WM) patients in first line and in relapse. The combination of anti-CD20 monoclonal antibody with chemotherapy or with bortezomib remains a recommended therapy in most patients with WM. Most of the published series are small phase II trials using rituximab in combination with alkylating agents (cyclophosphamide), with purine analogues (fludarabine) with or without alkylating agents, and with proteasome inhibitors (bortezomib). The studies with new anti-CD20 monoclonal antibodies (ofatumumab, ubituzumab) or with anti-CD52 and anti-CD22 monoclonal antibodies are scarce. The choice of immunochemotherapy depends on the patient’s comorbidities, the toxicity, and the need of hematopoietic stem cell collection. Chemo-free combinations with new target agents such as BCR inhibitors are promising.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Buske C, Leblond V. How to manage Waldenstrom’s macroglobulinemia. Leukemia. 2013;4:762–72.

    Article  Google Scholar 

  2. Buske C, Leblond V, Dimopoulos M, Kimby E, Jäger U, Dreyling M, ESMO Guidelines Working Group. Waldenstrom’s macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Suppl 6:vi155–9.

    Google Scholar 

  3. Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, et al. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014;124:1404–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR. Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma. 2004;45:2047–55.

    Article  CAS  PubMed  Google Scholar 

  5. Treon SP, Agus DB, Link B, Rodrigues G, Molina A, Lacy MQ, et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom’s macroglobulinemia. J Immunother. 2001;24:272–79.

    Article  CAS  Google Scholar 

  6. Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki V, et al. Treatment of Waldenström’s macroglobulinemia with rituximab. J Clin Oncol. 2002;20:2327–33.

    Article  CAS  PubMed  Google Scholar 

  7. Treon SP, Emmanouilides C, Kimby E, Kelliher A, Preffer F, Branagan AR, et al. Extended rituximab therapy in Waldenström’s macroglobulinemia. Ann Oncol. 2005;16:132–38.

    Article  CAS  PubMed  Google Scholar 

  8. Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole DH, et al. Initial immunoglobulin M “flare” after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004;101:2593–8.

    Article  CAS  PubMed  Google Scholar 

  9. Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore). 2010;89:308–18.

    Article  Google Scholar 

  10. Wolach O, Shpilberg O, Lahav M. Neutropenia after rituximab treatment: new insights on a late complication. Curr Opin Hematol. 2012;19:32–8.

    Article  CAS  PubMed  Google Scholar 

  11. Li SC, Chen YC, Evens AM, Lee CC, Liao HF, Yu CC, Tung YT, et al. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism. Am J Hematol. 2010;85:810–2.

    Article  PubMed  Google Scholar 

  12. Furman RR, Eradat H, Switzky J. A phase II trial of Ofatumumab in subjects with Waldenstrom’s macroglobulinemia. Blood. 2011: 118: Abstract 3701.

    Google Scholar 

  13. Treon SP, Hanzis C, Tripsas C, Ioakimidis L, Patterson CJ, Manning RJ, Sheehy P. Bendamustine therapy in patients with relapsed or refractory Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011;1:133–5.

    Article  Google Scholar 

  14. Treon SP, Soumerai JD, Hunter ZR, Patterson CJ, Ioakimidis L, Kahl B, et al. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström’ macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood. 2011;118:276–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Treon SP, Hanzis C, Manning RJ, Ioakimidis L, Patterson CJ, Hunter ZR, et al. Maintenance rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol. 2011;154:357–62.

    Article  CAS  PubMed  Google Scholar 

  16. Bishton M, Spencer A, Dickinson M, Ritchie D. A single-arm, phase II study of the anti-blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013;13:575–78.

    Article  CAS  PubMed  Google Scholar 

  17. Le Garff-Tavernier M, Herbi L, de Romeuf C, Azar N, Roos-Weil D, Bonnemye P, et al. The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia. Haematologica. 2015;10:147–51.

    Article  Google Scholar 

  18. Buske C, Hoster E, Dreyling M, Eimermacher H, Wandt H, Metzner B, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009;23:153–61.

    Article  CAS  PubMed  Google Scholar 

  19. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C, Kokkinis G, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007;25:3344–49.

    Article  CAS  PubMed  Google Scholar 

  20. Dimopoulos MA, Maria Roussou M, Kastritis E, Hadjiharissi E, Kyrtsonis MC, Symeonidis A, et al. Primary treatment of Waldenstrom’s macroglobulinemia with dexamethasone, rituximab and cyclophosphamide (DRC): final analysis of a phase II study. Blood. 2012;120:438.

    Google Scholar 

  21. Ioakimidis L, Patterson CJ, Hunter ZR, Soumerai JD, Manning RJ, Turnbull B, et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma. 2009;9:62–6.

    Article  CAS  PubMed  Google Scholar 

  22. Treon SP, Ioakimidis L, Patterson CJ, Soumerai JD, Sheehy P, Nelson M, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05–180. J Clin Oncol. 2009;27:3830–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Treon SP, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis L, et al. Lenalidomide and rituximab in Waldenstrom’s macroglobulinemia. Clin Cancer Res. 2009;15:355–60.

    Article  CAS  PubMed  Google Scholar 

  24. Laszlo D, Andreola G, Rigacci L, Fabbri A, Rabascio C, Mancuso P, et al. Rituximab and subcutaneous 2-chloro-2’-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol. 2010;28:2233–38.

    Article  CAS  PubMed  Google Scholar 

  25. Tam CS, Wolf M, Prince HM, Januszewicz EH, Westerman D, Lin KI, et al. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer. 2006;106:2412–20.

    Article  CAS  PubMed  Google Scholar 

  26. Tedeschi A, Benevolo G, Varettoni M, Battista ML, Zinzani PL, Visco C, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer. 2012;118:434–43.

    Article  CAS  PubMed  Google Scholar 

  27. Souchet L, Levy V, Ouzegdouh M, Tamburini J, Delmer A, Dupuis J, et al. Efficacy and long-term toxicity of rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom’s macroglobulinemia. Am J Hematol. 2016 May 2. doi: 10.1002/ajh.24405. [Epub ahead of print].

  28. Tedeschi A, Ricci F, Goldaniga MC, Benevolo G, Varettoni M, Motta M, et al. Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013;2:208–10.

    Google Scholar 

  29. Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom’s macroglobulinemia. Semin Oncol. 2003;30:243–47.

    Article  CAS  PubMed  Google Scholar 

  30. Treon SP, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis L, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood. 2008;112:4452–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–10.

    Article  CAS  PubMed  Google Scholar 

  32. Tedeschi A, Picardi P, Ferrero S, Benevolo G, Margiotta Casaluci G, et al. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. Leuk Lymphoma. 2015;56:2637–42.

    Article  PubMed  Google Scholar 

  33. Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010;28:1422–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Dimopoulos MA, García-Sanz R, Gavriatopoulou M, Morel P, Kyrtsonis MC, Michalis E, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013;122:3276–82.

    Article  CAS  PubMed  Google Scholar 

  35. Cao Y, Hunter ZR, Liu X, Xu L, Yang G, Chen J, et al. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P)-directed survival signalling in Waldenström macroglobulinaemia cells. Br J Haematol. 2015;168:701–7.

    Article  CAS  PubMed  Google Scholar 

  36. Treon SP, Tripsas CK, Meid K, Kanan S, Sheehy P, Chuma S, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström’s macroglobulinemia. Blood. 2014;124:503–10.

    Article  CAS  PubMed  Google Scholar 

  37. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med. 2015;372:1430–40.

    Article  CAS  PubMed  Google Scholar 

  39. Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113:4163–70.

    Article  CAS  PubMed  Google Scholar 

  40. Dimopoulos MA, Kastritis E, Delimpassi S, Zomas A, Kyrtsonis MC, Zervas K. The international prognostic scoring system for Waldenstrom’s macroglobulinemia is applicable in patients treated with rituximab-based regimens. Haematologica. 2008;93:1420–2.

    Article  CAS  PubMed  Google Scholar 

  41. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014;15:69–77.

    Article  CAS  PubMed  Google Scholar 

  42. Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström macroglobulinemia. Am J Hematol. 2010;85:670–74.

    Article  CAS  PubMed  Google Scholar 

  43. Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström’s macroglobulinemia. J Clin Oncol. 2005;23:474–81.

    Article  CAS  PubMed  Google Scholar 

  44. Treon SP, Branagan AR, Ioakimidis L, Soumerai JD, Patterson CJ, Turnbull B, et al. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood. 2009;113:3673–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. APHP Hôpital Pitié-Salpêtrière, UPMC Paris 6 GRC-11, GRECHY, Paris, France

    Véronique Leblond, Laetitia Souchet & Sylvain Choquet

  2. Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany

    Christian Buske

Authors
  1. Véronique Leblond
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laetitia Souchet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sylvain Choquet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christian Buske
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Véronique Leblond .

Editor information

Editors and Affiliations

  1. Haematology, Hôpital Pitié-Salpêtriêre, Paris, France

    Véronique Leblond

  2. Dana Farber Cancer Institute, Boston, Massachusetts, USA

    Steve Treon

  3. School of Medicine, University of Athens, Athens, Greece

    Meletios Dimoploulos

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Leblond, V., Souchet, L., Choquet, S., Buske, C. (2017). Immunotherapy in Waldenstrom’s Macroglobulinemia. In: Leblond, V., Treon, S., Dimoploulos, M. (eds) Waldenström’s Macroglobulinemia. Springer, Cham. https://doi.org/10.1007/978-3-319-22584-5_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22584-5_21

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22583-8

  • Online ISBN: 978-3-319-22584-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation